0001214659-21-001271.txt : 20210204
0001214659-21-001271.hdr.sgml : 20210204
20210204165738
ACCESSION NUMBER: 0001214659-21-001271
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210202
FILED AS OF DATE: 20210204
DATE AS OF CHANGE: 20210204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Finn Patrick John
CENTRAL INDEX KEY: 0001755970
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38720
FILM NUMBER: 21591950
MAIL ADDRESS:
STREET 1: C/O TWIST BIOSCIENCE CORPORATION
STREET 2: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Twist Bioscience Corp
CENTRAL INDEX KEY: 0001581280
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462058888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 681 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 800-719-0671
MAIL ADDRESS:
STREET 1: 681 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
marketforms-51368.xml
PRIMARY DOCUMENT
X0306
4
2021-02-02
0001581280
Twist Bioscience Corp
TWST
0001755970
Finn Patrick John
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Commercial Officer
Common Stock
2021-02-02
4
M
false
358
8.82
A
44385
D
Common Stock
2021-02-02
4
M
false
1517
26.66
A
45902
D
Common Stock
2021-02-02
4
M
false
827
23.33
A
46729
D
Common Stock
2021-02-02
4
S
false
2702
183.59
D
44027
D
Employee Stock Option (right to buy)
8.82
2021-02-02
4
M
false
358
0
D
2027-09-28
Common Stock
358
18131
D
Employee Stock Option (right to buy)
26.66
2021-02-02
4
M
false
1517
0
D
2028-11-18
Common Stock
1517
50061
D
Employee Stock Option (right to buy)
23.33
2021-02-02
4
M
false
827
0
D
2029-10-23
Common Stock
827
27302
D
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020.
The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
/s/ William Solis, as Attorney-in-Fact for Patrick John Finn
2021-02-04